Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch & Lomb CorpBLCO · Entity 3756 | Director | May 26, 2026 | May 28, 2026 |
| Bausch Health Companies Inc.BHC · Entity 4363 | Director | March 29, 2024 | April 01, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch & Lomb Corp
Report date May 26, 2026 · Filed May 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 94,260 |
Reported balance
After 2026-05-26 transaction · row 1
1 source rowRow 1 · 2026-05-26 · Grant · Acquired 15,842 · Balance 94,260 F1: Reflects the annual grant of restricted share units ("RSUs") to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the annual grant of restricted share units ("RSUs") to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders.
Bausch Health Companies Inc.
Report date March 29, 2024 · Filed April 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 225,279 |
Reported balance
After 2024-03-29 transaction · row 1
1 source rowRow 1 · 2024-03-29 · Grant · Acquired 2,945 · Balance 225,279 F1: Reflects Restricted Share Units, each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects Restricted Share Units, each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2018 Filed May 4, 2018 22:01 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016412 · form4.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,498 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. Read SEC document |
| May 03, 2018 Filed May 8, 2018 20:39 UTC Amendment | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 13,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016655 · form4a.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,094 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. F2 · shares: This Amended Form 4 is being filed to correct the number of RSUs acquired on May 3, 2018 as reported on the Form 4 filed on May 4, 2018. Read SEC document |
| March 30, 2018 Filed Apr 3, 2018 20:56 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 2,355 | $15.92 | $37,491.60 |
DisclosureSEC source: 0001127602-18-013761 · form4.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,213 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 16:19 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 1,804 | $20.78 | $37,487.12 |
DisclosureSEC source: 0001127602-18-000372 · form4.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,858 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 21:44 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 2,616 | $14.33 | $37,487.28 |
DisclosureSEC source: 0001127602-17-029034 · form4.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,054 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 22:05 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 2,167 | $17.30 | $37,489.10 |
DisclosureSEC source: 0001127602-17-023071 · form4.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,438 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| May 05, 2017 Filed May 5, 2017 21:27 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 25,406 | $0.00 | $0.00 |
DisclosureSEC source: 0000885590-17-000029 · primary_doc.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,271 F1 · shares: Regular annual Restricted Share Units (RSUs) equal to $250,000 granted to non-employee directors in office on the third trading day following the Annual Meeting of Shareholders based on the closing price of registrant common stock on the date prior to the grant. RSUs represent a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:02 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 3,127 | $11.03 | $34,490.81 |
DisclosureSEC source: 0000885590-17-000022 · primary_doc.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,865 F1 · shares: Represents Restricted Share Units (RSUs) representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| December 30, 2016 Filed Jan 5, 2017 00:52 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 2,324 | $14.52 | $33,744.48 |
DisclosureSEC source: 0001677301-17-000001 · primary_doc.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,738 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 21:08 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 1,376 | $24.55 | $33,780.80 |
DisclosureSEC source: 0001677300-16-000009 · primary_doc.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,414 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.